Disease/Infection News

RSS

Bioxodes completes seed funding round to bring Ir-CPI product into pre-clinical development

Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company’s lead product Ir-CPI into pre-clinical development over the next 18 months.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds developed by UC Irvine structural biologists and Northwestern University chemists have been shown to bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

27 Nov 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

MSF launches film series to counterbalance rhetoric presenting the fight against HIV/AIDS as almost won

The fight against HIV/AIDS has been hailed as one of the most successful public health projects in human history, but teams from the international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) see the revolution as unfulfilled for millions of people excluded from treatment.

26 Nov 2013

HPV vaccine coverage among teens still remains low than other recommended vaccinations

Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication.

26 Nov 2013

HIV patients face higher risk of virologic failure than previously thought

People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine.

26 Nov 2013

New concept outlines steps to tackle neglected tropical diseases, expedite poverty reduction efforts

A new concept and policy framework published in PLOS NTDs outlines concrete steps for the global development community as it works to synthesize health goals with economic, environmental and social priorities.

26 Nov 2013

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

The application for European marketing authorisation of faldaprevir, a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency (EMA).

26 Nov 2013

Researchers identify key immune cells that turn body's defenders against invading golden staph

When golden staph enters our skin it can identify the key immune cells and 'nuke' our body's immune response.

26 Nov 2013

Pediatrician analyzes management of the 2009 influenza A crisis

With autumn just around the corner and a new flu strain lying in wait for us, the presentation of a study analysing the management of the 2009 influenza A crisis could not, if anything, be better timed.

26 Nov 2013

Garlic compounds can kill foodborne pathogen present in infant formula powder

Garlic may be bad for your breath, but it's good for your baby, according to a new study from the University of British Columbia.

26 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells.

25 Nov 2013

Researchers identify immune cell protein that sets off body's initial response against viral infection

A Massachusetts General Hospital-led research team has identified an immune cell protein that is critical to setting off the body's initial response against viral infection. The report that will be published in an upcoming issue of Nature Immunology and is receiving early online release describes finding that a protein called GEF-H1 is essential to the ability of macrophages - major contributors to the innate immune system - to respond to viral infections like influenza.

25 Nov 2013

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.

25 Nov 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

A study of 2,519 Kenyan men conducted by researchers at the University of North Carolina revealed that infection with the human papillomavirus (HPV) was associated with a higher subsequent risk of infection with HIV, a precursor to AIDS.

25 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

New bill offers hope to HIV patients on transplant waiting lists

A bill scheduled to be signed into law today by President Obama reverses the longtime ban on letting HIV-infected people donate their organs for transplantation after death, a move that offers hope to thousands of HIV patients on transplant waiting lists.

22 Nov 2013

Disease/Infection News

Bioxodes completes seed funding round to bring Ir-CPI product into pre-clinical development

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

EU-funded project develops new type of vaccine to tackle HIV virus infection

MSF launches film series to counterbalance rhetoric presenting the fight against HIV/AIDS as almost won

HPV vaccine coverage among teens still remains low than other recommended vaccinations

HIV patients face higher risk of virologic failure than previously thought

New concept outlines steps to tackle neglected tropical diseases, expedite poverty reduction efforts

EMA grants accelerated assessment to Boehringer Ingelheim's Faldaprevir compound

Researchers identify key immune cells that turn body's defenders against invading golden staph

Pediatrician analyzes management of the 2009 influenza A crisis

Garlic compounds can kill foodborne pathogen present in infant formula powder

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers identify immune cell protein that sets off body's initial response against viral infection

CHMP recommends approval of Otsuka's Deltyba for pulmonary multidrug-resistant tuberculosis

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

New bill offers hope to HIV patients on transplant waiting lists

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News